Crohn's disease: Ustekinumab induces rapid symptom reduction

被引：0
|
作者：
Simon, Annika
机构：
来源：
ZEITSCHRIFT FUR GASTROENTEROLOGIE | 2024年 / 62卷 / 05期
关键词：
D O I：
10.1055/a-2253-5211
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Ustekinumab ist ein humaner monoklonaler IgG1 kappa -Antikorper gegen Interleukin (IL)-12/23 und ist zur Behandlung von Autoimmunerkrankungen wie Psoriasis und Morbus Crohn (MC) indiziert. Da die Ustekinumab-Reaktionsdynamik fur MC-PatientInnen im Rahmen der Therapieplanung meist eine besondere Rolle spielt, haben Colombel et al. diese auf Basis der Daten mehrerer MC-Studien einmal genauer betrachtet.
引用
收藏
页码：699 / 701
页数：2
相关论文
共 50 条
  • [21] Ustekinumab vs adalimumab for Crohn's disease
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (09): : 793 - 793
  • [22] Experience with ustekinumab in reservoir Crohn's disease
    Martinez Burgos, Maria
    Angulo McGrath, Isabela
    Amo Trillo, Victor
    Olmedo Martin, Raul
    Romero Cara, Patricia
    Mostazo Torres, Jose
    Jimenez Perez, Miguel
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2022, 114 (04) : 233 - 234
  • [23] Hypersensitivity to IV Ustekinumab but Tolerance to Subcutaneous Ustekinumab in a Patient With Crohn's Disease
    Cleveland, Noa Krugliak
    Masching, Alexandra
    Rubin, David T.
    ACG CASE REPORTS JOURNAL, 2020, 7 (08)
  • [24] Hypersensitivity to IV Ustekinumab but Tolerance to Subcutaneous Ustekinumab in a Patient With Crohn's Disease
    Cleveland, Noa Krugliak
    Masching, Alexandra
    Rubin, David T.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S1168 - S1168
  • [25] Ustekinumab effectiveness in Crohn's disease with lesions in the intestines
    Tamura, Satoshi
    Asai, Yusuke
    Ishida, Natsuki
    Miyazu, Takahiro
    Tani, Shinya
    Yamade, Mihoko
    Hamaya, Yasushi
    Iwaizumi, Moriya
    Osawa, Satoshi
    Furuta, Takahisa
    Sugimoto, Ken
    MEDICINE, 2024, 103 (15) : E35647
  • [26] Ustekinumab: A Review in Moderate to Severe Crohn’s Disease
    Yvette N. Lamb
    Sean T. Duggan
    Drugs, 2017, 77 : 1105 - 1114
  • [27] Intensification with intravenous ustekinumab in refractory Crohn′s disease
    Arroyo Arguelles, J. M.
    Suarez Ferrer, C.
    Rueda Garcia, J. L.
    Martin-Arranz, E.
    Poza Cordon, J.
    Sanchez-Azofra, M.
    Garcia-Ramirez, L.
    Martin-Arranz, M. D.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 866 - 868
  • [28] Successful Treatment of Oral Crohn's Disease by Ustekinumab
    Jukema, Jelmer B.
    Brandse, Johannan F.
    de Boer, Nanne K. H.
    INFLAMMATORY BOWEL DISEASES, 2020, 26 (03) : E19 - E19
  • [29] Ustekinumab in Crohn's disease: experience in a regional hospital
    Trujillano, A.
    Maestre, M. A.
    Galan, N.
    Cano, V.
    Morego, A.
    Bello, M.
    Llodra, V.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2021, 43 (03) : 815 - 815
  • [30] Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
    Feagan, B. G.
    Sandborn, W. J.
    Gasink, C.
    Jacobstein, D.
    Lang, Y.
    Friedman, J. R.
    Blank, M. A.
    Johanns, J.
    Gao, L. -L.
    Miao, Y.
    Adedokun, O. J.
    Sands, B. E.
    Hanauer, S. B.
    Vermeire, S.
    Targan, S.
    Ghosh, S.
    de Villiers, W. J.
    Colombel, J. -F.
    Tulassay, Z.
    Seidler, U.
    Salzberg, B. A.
    Desreumaux, P.
    Lee, S. D.
    Loftus, E. V., Jr.
    Dieleman, L. A.
    Katz, S.
    Rutgeerts, P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (20): : 1946 - 1960
12345